File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Nutraceuticals and their preventive or potential therapeutic value in Parkinson's disease

TitleNutraceuticals and their preventive or potential therapeutic value in Parkinson's disease
Authors
Issue Date2012
Citation
Nutrition Reviews, 2012, v. 70 n. 7, p. 373-386 How to Cite?
AbstractParkinson's disease (PD) is the second most common aging-related disorder in the world, after Alzheimer's disease. It is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta and other parts of the brain, leading to motor impairment, cognitive impairment, and dementia. Current treatment methods, such as L-dopa therapy, are focused only on relieving symptoms and delaying progression of the disease. To date, there is no known cure for PD, making prevention of PD as important as ever. More than a decade of research has revealed a number of major risk factors, including oxidative stress and mitochondrial dysfunction. Moreover, numerous nutraceuticals have been found to target and attenuate these risk factors, thereby preventing or delaying the progression of PD. These nutraceuticals include vitamins C, D, E, coenzyme Q10, creatine, unsaturated fatty acids, sulfur-containing compounds, polyphenols, stilbenes, and phytoestrogens. This review examines the role of nutraceuticals in the prevention or delay of PD as well as the mechanisms of action of nutraceuticals and their potential applications as therapeutic agents, either alone or in combination with current treatment methods. © 2012 International Life Sciences Institute.
Persistent Identifierhttp://hdl.handle.net/10722/179288
ISSN
2015 Impact Factor: 5.591
2015 SCImago Journal Rankings: 3.001
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChao, Jen_US
dc.contributor.authorLeung, Yen_US
dc.contributor.authorWang, Men_US
dc.contributor.authorChang, RCCen_US
dc.date.accessioned2012-12-19T09:53:49Z-
dc.date.available2012-12-19T09:53:49Z-
dc.date.issued2012en_US
dc.identifier.citationNutrition Reviews, 2012, v. 70 n. 7, p. 373-386en_US
dc.identifier.issn0029-6643en_US
dc.identifier.urihttp://hdl.handle.net/10722/179288-
dc.description.abstractParkinson's disease (PD) is the second most common aging-related disorder in the world, after Alzheimer's disease. It is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta and other parts of the brain, leading to motor impairment, cognitive impairment, and dementia. Current treatment methods, such as L-dopa therapy, are focused only on relieving symptoms and delaying progression of the disease. To date, there is no known cure for PD, making prevention of PD as important as ever. More than a decade of research has revealed a number of major risk factors, including oxidative stress and mitochondrial dysfunction. Moreover, numerous nutraceuticals have been found to target and attenuate these risk factors, thereby preventing or delaying the progression of PD. These nutraceuticals include vitamins C, D, E, coenzyme Q10, creatine, unsaturated fatty acids, sulfur-containing compounds, polyphenols, stilbenes, and phytoestrogens. This review examines the role of nutraceuticals in the prevention or delay of PD as well as the mechanisms of action of nutraceuticals and their potential applications as therapeutic agents, either alone or in combination with current treatment methods. © 2012 International Life Sciences Institute.en_US
dc.languageengen_US
dc.relation.ispartofNutrition Reviewsen_US
dc.subject.meshDietary Supplementsen_US
dc.subject.meshDisease Progressionen_US
dc.subject.meshHumansen_US
dc.subject.meshMitochondria - Drug Effects - Metabolism - Physiologyen_US
dc.subject.meshOxidative Stress - Drug Effectsen_US
dc.subject.meshParkinson Disease - Prevention & Control - Therapyen_US
dc.subject.meshRisk Factorsen_US
dc.titleNutraceuticals and their preventive or potential therapeutic value in Parkinson's diseaseen_US
dc.typeArticleen_US
dc.identifier.emailWang, M: mfwang@hku.hken_US
dc.identifier.emailChang, RCC: rccchang@hku.hken_US
dc.identifier.authorityWang, M=rp00800en_US
dc.identifier.authorityChang, RCC=rp00470en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1753-4887.2012.00484.xen_US
dc.identifier.pmid22747840-
dc.identifier.scopuseid_2-s2.0-84863314750en_US
dc.identifier.hkuros204905-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84863314750&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume70en_US
dc.identifier.issue7en_US
dc.identifier.spage373en_US
dc.identifier.epage386en_US
dc.identifier.isiWOS:000305885100001-
dc.identifier.scopusauthoridChao, J=24558959000en_US
dc.identifier.scopusauthoridLeung, Y=55279954100en_US
dc.identifier.scopusauthoridWang, M=7406691844en_US
dc.identifier.scopusauthoridChang, RCC=7403713410en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats